Table 2.
Recipients from deceased donor with VITT
| Organ transplanted | Number of Recipients | Median Age in Years (Range) | Female n(%) | Hemorrhage (n) | Thrombosis (n) | DGF/ Early Graft Dysfunction (n) | Graft Loss With Explants (n) | Graft Loss (n) | Patient Loss(n) | PF4 Antibodies (n) | Platelet Count 109/L | Follow-up Mean (Range) days | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Greenhall et al 8 | Kidney | 15 | 40 (2-63) | 12(46%) | 3 | 1 | 4 | 1 | 2 | 1 | 3 | 124 (32 – 267) | 19(21-27) |
| SPK | 1 | 0 | 0 | 0 | |||||||||
| Islet cell transplant | 1 | 0 | 0 | 0 | |||||||||
| liver | 7 | 0 | 3 | 2 | 0 | ||||||||
| Heart | 1 | 0 | 0 | 0 | 0 | ||||||||
| Lung | 1 | 0 | 0 | 0 | 0 | ||||||||
| Centonze et al 10 | Liver | 1 | 62 | 1(100%) | 0 | 1 (Hepatic vein from donor) | 0 | 0 | 0 | 0 | 0 | 2 15 000/mm3 | 60 |
| Loupy et al 9 | Kidney | 6 | 60(42-70) | 2 (33.3%) | 1(peri graft) | 2 (glomerular) | 2(recovered) | 0 | 0 | 0 | 0(1 NA) | 152 (87-207 | 52 (16-77) |
| Heart and liver | 1 | 64 | 0 | 0 | 0 | 0 | 0 | 120 | |||||
| Heart | 1 | 54 | 0 | 0 | 0 | 0 | 0 | 130 | |||||
| Lung | 1 | 58 | 1(100%) | 0 | Pulmonary thromboembolism | 0 | 0 | 465 | |||||
| Present study | Kidney | 2 | 22, 31 | 1(50%) | 0 | 0 | 0 | 0 | 0 | 0 | Not tested | 150000 | 120 |
| Liver | 1 | 64 | 1(100%) | 60,000 | |||||||||
| Heart and lung | 1 | 26 | 1(100%) | 125000 | |||||||||
| NHS Blood and transplantation INF1569/3.1 7 |
Kidney | 30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Liver | 9 | ||||||||||||
| Heart | 3 | ||||||||||||
| Lung | 1 | ||||||||||||
| Islet cell | 1 | ||||||||||||
| SPK | 1 |
DGF, delayed graft function; NA, not available; SPK, simultaneous pancreas and kidney transplant; VITT, vaccine-induced thrombotic thrombocytopenia.